FDA称，礼来两款替尔泊肽成分GLP-1注射剂Zepbound和Mounjaro 2022年来一直因需求增长而供应短缺，现认定短缺问题解决。行业组织称，FDA的认定等于让药房停止配置和分发两款药的仿制药。

在分析师评级方面，BMO Capital维持礼来的"优于大市"评级，对公司新任首席财务官Lucas Montarce表示信心。德意志银行和Cantor Fitzgerald也分别维持了公司的买入和增持评级。

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

In a phased rollout, the jabs eventually will be offered to those with a BMI of 35 or more and weight-related health problems ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

智通财经APP获悉，美国食品药品管理局(FDA)宣布，礼来公司(LLY.US)的畅销减肥和糖尿病药物Zepbound和Mounjaro的短缺问题已得到解决，这可能会对市场上流行的仿制品造成冲击。此前，由于药物短缺，FDA允许药房出售未经严格测试的仿制 ...

NHS leaders consider phased roll out of Mounjaro obesity jab to combat high demand - Nearly a quarter of a million people are ...

NHS says a quarter of a million people will be offered tirzepatide - brand name Mounjaro - after trials showed it helped obese participants lose a fifth of their body weight ...

据媒体报道，在评级暂停一段时间后，花旗银行恢复了对减肥药巨头礼来的评级，给予“买入”评级，目标价1060美元/股，理由是看好该公司的GLP-1产品线销售额前景，其中包括其畅销的有着“减肥神药”称号畅销减肥药物Zepbound，该药物的核心成分为替尔泊 ...

Dr Simon Cork, Senior Lecturer in Physiology, Anglia Ruskin University (ARU), said: ...

A class of drugs that includes popular medications like Ozempic, Wegovy, Rybelsus (semaglutide) or Mounjaro and Zepbound (tirzepatide) has not only proven effective in treating weight loss and ...